Generation Bio Co. (GBIO) Reports Q4 Loss, Tops Revenue Estimates

Group 1 - Generation Bio Co. reported a quarterly loss of $0.32 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.28, and an improvement from a loss of $0.53 per share a year ago, indicating an earnings surprise of -14.29% [1] - The company posted revenues of $4.19 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 6.95%, and showing an increase from year-ago revenues of $2.88 million [2] - Generation Bio shares have declined approximately 50.5% since the beginning of the year, contrasting with the S&P 500's decline of -4.8% [3] Group 2 - The earnings outlook for Generation Bio is mixed, with the current consensus EPS estimate for the coming quarter at -$0.28 on revenues of $0.86 million, and for the current fiscal year at -$0.95 on revenues of $9.52 million [7] - The Medical - Biomedical and Genetics industry, to which Generation Bio belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]